Chlorcyclizine; Pseudoephedrine

Drug Usage Statistics, United States, 2013 - 2022

ClinCalc.com » Pharmacy » ClinCalc DrugStats » Chlorcyclizine; Pseudoephedrine

Chlorcyclizine; Pseudoephedrine Summary for 2022

Top drug rank	#386 (no previous rank)
Estimated number of prescriptions in the United States (2022)	10,927
Estimated number of patients in the United States (2022)	10,927
Average total drug cost (USD)
Per prescription	$13.98
Per day of therapy	$2.00/day
Average out-of-pocket cost (USD)
Per prescription	$13.98
Per day of therapy	$2.00/day

Total Prescriptions and Patients Per Year (2013 - 2022)

Rank of Top Drugs Over Time

"Rank" refers to the frequency that a given medication is prescribed within a calendar year compared to all other medications. A rank of "4" would indicate that the medication was the fourth most commonly prescribed medication.

Drug Cost Over Time (2013 - 2022)

Cost Per Prescription Fill (USD)

Cost Per Day of Therapy (USD/day)

Distribution of Dispensed Dosage Forms (2022)

Distribution of Days Supplied (2022)

"Days supply" is defined as the number of days that a prescription should last. For example, a prescription of 60 tablets that is taken twice daily has a day supply of 30 days.

Drug Synonyms

Drug synonyms are used during the sanitation and standardization process of "cleaning" the original data source (MEPS). Occassionally, brand names may be listed below that are no longer on the market or are very infrequently used.

FDA Approval Information

Established Pharmacologic Class (EPC):	alpha-Adrenergic Agonist
Initial FDA approval date:	12/20/2011
First FDA applicant:	Magna Pharmaceuticals, Inc.
First dosage form:	Tablet (oral)

---

Prescription data source: Medical Expenditure Panel Survey (MEPS) 2013-2022. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 2024.08. Read more about the ClinCalc DrugStats database.

All ClinCalc DrugStats figures and graphs on this page are licensed under Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0).